Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

InterMune stock plunges 80% as FDA rejects lung drug

By Hibah Yousuf, staff reporter


NEW YORK (CNNMoney.com) -- Shares of InterMune Inc. plunged nearly 80% after-hours Tuesday following the Food and Drug Administration's rejection of the biotech company's application for Esbriet, a drug designed to treat a fatal lung disease.

The company said the FDA has requested an additional clinical trial to support the effectiveness of Esbriet in patients suffering from idiopathic pulmonary fibrosis, which hinders the body's ability to process oxygen due to inflammation and scarring in the lungs.

"We will meet with the FDA as soon as possible to understand their points of view and to determine the most appropriate path forward to expeditiously make Esbriet available to the approximately 100,000 patients with IPF and their families who suffer from this terrible disease and for whom no FDA-approved medicines exist," InterMune (ITMN) chairman and chief executive Dan Welch said in a prepared statement.

Welch said he was "disappointed" by the outcome, since the FDA's advisory committee recommended the approval of the drug by a 9-3 margin in March.  To top of page

Index Last Change % Change
Dow 24,386.03 56.87 0.23%
Nasdaq 6,875.08 35.00 0.51%
S&P 500 2,659.99 8.49 0.32%
Treasuries 2.40 0.01 0.55%
Data as of 9:02am ET
Company Price Change % Change
Mondelez Internation... 42.87 0.22 0.52%
KeyCorp 19.73 -0.16 -0.80%
Exelon Corp 41.92 0.87 2.12%
Newmont Mining Corp 34.67 -0.73 -2.06%
PPL Corp 34.62 0.12 0.35%
Data as of Dec 11
Sponsors

Sections

More than 5% of DACA recipients have started their own businesses since enrolling the program, according to a recent survey. More

Former President Obama thanked those helping Americans enroll in Obamacare. He then took to Twitter and Facebook to remind people that the deadline to sign up is Dec. 15. More

The company said on Tuesday its hybrid gaming system -- one part mobile, one part home console -- sold 10 million units since its March 2017 launch. More